SCHEMBL19852954

SCHEMBL19852954

Cc1ccc(S(=O)(=O)Nc2cccc3cnccc23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.62
KMT2A Q03164 5/20 0.60
ALDH1A1 P00352 4/20 0.60
MAPT P10636 4/20 0.60
TDP1 Q9NUW8 3/20 0.60
HTT P42858 2/20 0.60
LMNA P02545 2/20 0.60
SLC40A1 Q9NP59 2/20 0.60
CKS1B P61024 2/20 0.60
SKP2 Q13309 2/20 0.60
MITF O75030 1/20 0.60
S1PR4 O95977 1/20 0.60
S1PR1 P21453 1/20 0.60
AGTR1 P30556 1/20 0.60
OPRK1 P41145 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
MEN1 O00255 4/20 0.56
KEAP1 Q14145 1/20 0.56
NFE2L2 Q16236 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737441 0.89 IDO1 (0.62) IDO1KMT2AALDH1A1MAPTTDP1
SCHEMBL19852956 0.87 RECQL (0.69) IDO1KMT2AALDH1A1MAPTTDP1
SCHEMBL17737675 0.87 IDO1 (0.63) IDO1KMT2AALDH1A1MAPTTDP1
SCHEMBL15452718 0.86 IDO1 (0.62) IDO1KMT2AALDH1A1MAPTHTT
SCHEMBL17737362 0.86 IDO1 (0.62) IDO1KMT2AALDH1A1MAPTHTT
SCHEMBL1040890 0.86 GLO1 (0.62) IDO1ALDH1A1HTTSMN1; SMN2POLB
SCHEMBL17737442 0.86 GLO1 (0.62) IDO1KMT2AALDH1A1MAPTTDP1
SCHEMBL17737766 0.85 IDO1 (0.61) IDO1KMT2AALDH1A1MAPTTDP1
SCHEMBL27214264 0.83 SLC40A1 (0.66) IDO1KMT2AALDH1A1MAPTTDP1
SCHEMBL19853016 0.83 TDP1 (0.65) IDO1KMT2AMAPTTDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 US disclosed
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 IDO1 3/4885KMT2A 1561/4885ALDH1A1 3640/4885
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 IDO1 3/4885KMT2A 1561/4885ALDH1A1 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.